<p>On June 10th, Merck announced that the Center for Drug Evaluation of the National Medical Products Administration of China has officially accepted its application for marketing authorization of the innovative Class 1 drug Pimicotinib, intended for adult patients with giant cell tumor of the tendon sheath requiring systemic treatment. Zhou Hong, Global Executive Vice President of Merck Pharmaceuticals and Head of China and International Markets, stated that the company is simultaneously advancing its application for marketing authorization to the U.S. FDA and plans to submit applications in other markets successively</p>

<p>On June 10th, Merck announced that the Center for Drug Evaluation of the National Medical Products Administration of China has officially accepted its application for marketing authorization of the Class 1 innovative drug Pimicotinib, intended for adult patients with tenosynovial giant cell tumors requiring systemic treatment. Zhou Hong, Executive Vice President of Global Pharmaceutical Health at Merck and Head of China and International Markets, stated that the company is simultaneously advancing its submission for marketing authorization to the U.S. FDA and plans to file in other markets successively</p>

默克治疗腱鞘巨细胞瘤的药物 Pimicotinib 上市许可申请获受理